

Syngene

Ref: Syn/CS/SE/Reg 30/2022-23/Nov/07

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

November 15, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
--	--

Dear Sir/Madam,

Subject: Update on USFDA Inspection of Biologics facility

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, this is to inform you that the US Food and Drug Administration (FDA) has conducted its pre-approval inspection of the Biologics facility at Bangalore from November 07, 2022 till November 15, 2022. The inspection was completed successfully without 483 observations.


The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Kindly take this intimation on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED



Priyadarshini Mahapatra
Company Secretary and Compliance Officer

